Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03168828 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury
A Phase 1 study of Neurogenic Detrusor Overactivity, sponsored by Taris Biomedical.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 4
- Study locations
NCT03168828 is a Phase 1 study of Neurogenic Detrusor Overactivity that has completed, run by Taris Biomedical. The registered enrollment target is 7 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT03168828, a Phase 1 study of Neurogenic Detrusor Overactivity, has completed, sponsored by Taris Biomedical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine if TAR-302-5018, an investigational drug-delivery system, is safe and tolerable in patients with neurogenic detrusor overactivity (NDO) resulting from spinal cord injury (SCI).
Conditions Studied
Interventions
- DRUG Trospium-Releasing Intravesical System (TAR-302-5018)
Study Locations (4)
Michigan
- Michigan Institute of Urology - Troy
North Carolina
- Carolinas HealthCare System - Charlotte
Virginia
- Urology of Virginia - Virginia Beach
Washington
- Virginia Mason - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2017-04-24 |
| Est. Completion | 2018-07-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03168828
The ClinicalTrials.gov registry entry for NCT03168828 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taris Biomedical, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neurogenic Detrusor Overactivity appearing as the primary indexed condition, and to 1 intervention - of which Trospium-Releasing Intravesical System (TAR-302-5018) is the first listed.
NCT03168828 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Michigan, North Carolina, Virginia.
Frequently Asked Questions
What is clinical trial NCT03168828 about?
NCT03168828 is a clinical study titled "Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury". The purpose of this study is to determine if TAR-302-5018, an investigational drug-delivery system, is safe and tolerable in patients with neurogenic detrusor overactivity (NDO) resulting from spinal cord injury (SCI).
What is the current status of trial NCT03168828?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2017-04-24. Estimated completion is 2018-07-26.
What conditions does trial NCT03168828 study?
This clinical trial studies the following conditions: Neurogenic Detrusor Overactivity.
What interventions are being tested in trial NCT03168828?
The interventions under investigation include: Trospium-Releasing Intravesical System (TAR-302-5018) (DRUG).
Who is sponsoring clinical trial NCT03168828?
This trial is sponsored by Taris Biomedical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03168828 being conducted?
This trial has 4 study locations across Michigan, North Carolina, Virginia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurogenic Detrusor Overactivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
RECRUITING · Phase 1
-
A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.